HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Batocchi, A. P. Articles by Tonali, P. Search for Related Content PubMed PubMed Citation Articles by Batocchi, A. P. Articles by Tonali, P.

Course and treatment of myasthenia gravis during pregnancy

From the Institute of Neurology, Catholic University, Rome, Italy.

Address correspondence and reprint requests to Dr. A.P. Batocchi, Institute of Neurology, Catholic University, L.go F. Vito, 1-00168 Rome, Italy.

OBJECTIVE: To evaluate the influence of myasthenia gravis (MG) on pregnancy and potential treatment risks for infants and mothers.

BACKGROUND: MG frequently affects young women in the second and third decades of life, overlapping with the childbearing years. Knowledge of the potential effects of 1) pregnancy on the course of MG and 2) the use of immunosuppressive drugs during pregnancy is limited, rendering decision-making difficult for both patient and physician.

METHODS: We studied 47 women who became pregnant after the onset of MG. Immunosuppressive drugs were administered when MG symptoms were not controlled with anticholinesterases. Sixty-four pregnancies resulted in 55 children and 10 abortions.

RESULTS: During pregnancy, MG relapsed in 4 of 23 (17%) asymptomatic patients who were not on therapy before conception; in patients taking therapy, MG symptoms improved in 12 of 31 pregnancies (39%), remained unchanged in 13 (42%), and deteriorated in 6 (19%). MG symptoms worsened after delivery in 15 of 54 (28%) pregnancies. Anti-acetylcholine receptor antibody (anti-AChR ab) was positive in 40 of 47 mothers and was assayed in 30 of 55 newborns; 13 were positive and 5 of 55 (9%) showed signs of neonatal MG (NMG). All affected babies were seropositive.

CONCLUSIONS: Pregnancy does not worsen the long-term outcome of MG. The course of the disease is highly variable and unpredictable during gestation and can change in subsequent pregnancies. The occurrence of NMG does not correlate with either maternal disease severity or anti-AChR antibody titer. Immunosuppressive therapy, plasmapheresis, and IV human immunoglobulins can be administered safely if needed.

This article has been cited by other articles:

				J. F. T. Zenteno Can we consider thymectomy before pregnancy in female patients with myasthenia gravis? Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 411 - 412. [Full Text] [PDF]

				T. C. Roth, J. Raths, G. Carboni, K. Rosler, and R. A. Schmid Effect of pregnancy and birth on the course of myasthenia gravis before or after transsternal radical thymectomy Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 231 - 235. [Abstract] [Full Text] [PDF]

				J. M. Hoff, A. K. Daltveit, and N. E. Gilhus Myasthenia gravis: Consequences for pregnancy, delivery, and the newborn Neurology, November 25, 2003; 61(10): 1362 - 1366. [Abstract] [Full Text] [PDF]

				A. Al-Shekhlee, N. Robin, H. J. Kaminski, A. Polizzi, M. Ruggieri, and A. Vincent Pyridostigmine-induced microcephaly Neurology, June 12, 2001; 56(11): 1606 - 1607. [Full Text] [PDF]